Tumor budding has been defined as a single tumor cell or small cluster of four or fewer tumor cells at the invasive front[@CR12],[@CR18] and should be considered a promising and strong prognostic factor in colorectal cancer (CRC).[@CR19] Widespread reporting of tumor budding has not progressed to routine clinical practice due to a lack of consensus on scoring methods. However, routine reporting is now advocated by using the approach outlined by the International Tumour Budding Consensus Conference (ITBCC), with recommendations for the assessment and reporting of tumor budding in CRC.[@CR6]

The ITBCC recommends that tumor budding should be included in future CRC guidelines and protocols and should be considered, along with other clinicopathological factors, in a multidisciplinary setting. The recent dataset for histopathological reporting of CRC by the royal pathologist stated that they would reconsider reporting tumor budding when new data become available.[@CR4]

The tumor microenvironment also plays an important role in CRC outcomes. Marked peritumoral inflammation has been associated with favorable outcome,[@CR3],[@CR14] while the presence of a high tumor stroma percentage (TSP) has been validated as a stage-independent marker of reduced survival in patients with primary operable CRC.[@CR7],[@CR8]. Both contribute to the development of a tumor microenvironment score that can potentially supplement the current TNM staging system.[@CR9]

The aim of this study was to assess the proposed method by ITBCC in clinical practice and investigate the relationship between tumor budding and tumor factors, tumor microenvironment, and survival in primary operable CRC.

Patients and Methods {#Sec1}
====================

Patients {#Sec2}
--------

Patients were identified from a prospectively collected database of patients undergoing surgery for CRC between 1997 and 2007 at the Royal Infirmary, Western Infirmary and Stobhill Hospital, Glasgow. Any patient with a synchronous cancer, inflammatory bowel disease, and mortality within 30 days of surgery, who had received neoadjuvant therapy, was excluded. Furthermore, patients who had their disease managed entirely endoscopically, without formal colonic or rectal resection, were also excluded from the study.

Patients were staged according to the TNM criteria that was applicable at the time of surgery and to current practice in the UK.[@CR4] The West of Scotland Research Ethics Committee granted study approval. Patients were followed up for at least 5 years, and the date and cause of death were cross-checked with electronic case records. Cancer-specific survival (CSS) was measured from the date of surgery until the date of death from CRC.

Routine Stains: Hematoxylin and Eosin and Elastica {#Sec3}
--------------------------------------------------

For evaluation, two consecutive cut samples from each specimen were stained; one was routinely stained with hematoxylin and eosin (H&E), and the other was stained with Miller's elastic stain (BDH, Poole, Dorset, UK) and counterstained with H&E. Routine pathological elastica staining was used to assess the presence of venous invasion.[@CR13]. Only venous invasion was evaluated and no special staining was utilized to improve the assessment of lymphatic or perineural invasion.

Assessment of Tumor Budding {#Sec4}
---------------------------

Tumor budding has been assessed on scanned H&E-stained slides in a single hotspot as defined by ITBCC. Tumor budding was counted on H&E slides, and was assessed in one hotspot (in a field measuring 0.785 mm^2^) at the invasive front. A two-tier system was used along with the budding count to facilitate risk stratification in CRC. Cut-offs used were: low, 0--9 buds; and high, ≥ 10 buds (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Example of **a** high tumor budding, **b** high inflammatory infiltrate (Klintrup--Makinen grade 4), and **c** high tumor stroma percentage

Tumor budding was evaluated by two different observers to ensure reliability, and co-scoring of randomly selected cases was carried out by HvW and PA. The interobserver intraclass correlation coefficient (ICCC) for the scores was 0.794 (*p* \< 0.001).

Evaluation of Tumor Inflammatory Cell Infiltrate and Tumor Stroma Percentage {#Sec5}
----------------------------------------------------------------------------

*Klintrup--Makinen grade* was used to assess the generalized inflammatory infiltrate semi-quantitatively. Full H&E sections of the deepest point of tumor invasion were used, whereby inflammatory cell density at the invasive margin was graded using a 4-point scale; it was classified as low-grade (no increase or mild/patchy increase in inflammatory cells) or high-grade (prominent inflammatory reaction forming a band at the invasive margin, or florid cup-like infiltrate at the invasive edge with destruction of cancer cell islands), as previously described[@CR3],[@CR14] (Fig. [1](#Fig1){ref-type="fig"}b).

*Tumor stroma percentage* was assessed semi-quantitatively using full sections of the deepest point of tumor invasion; the proportion of stroma was calculated as a percentage of the visible field, excluding areas of mucin deposition or necrosis. Tumors were subsequently graded as low (50%) or high (\> 50%) TSP as previously described[@CR8] (Fig. [1](#Fig1){ref-type="fig"}c).

Assessment of Ki-67, Mismatch Repair (MMR) and BRAF Status {#Sec6}
----------------------------------------------------------

The Ki-67 proliferation index was assessed cohort using a threshold of 50%. A subset of patients in the full cohort underwent evaluation of the mismatch repair (MMR) and BRAF statuses. Using immunohistochemistry, a previously constructed tissue microarray comprising cores of formalin-fixed paraffin-embedded cancer tissue was used to assess MMR and BRAF status. Immunohistochemistry for MMR status has been previously described.[@CR10] MMR protein expression was reported as MMR-competent or -deficient, by a single blinded observer. The assessment of BRAF status was performed as previously described by our group[@CR11] and therefore the results were incorporated in our study. BRAF V600E mutation was reported as absent or present by a single blinded observer.

Statistical Analysis {#Sec7}
--------------------

Interrelationships between tumor location, clinicopathological characteristics, and measures of the tumor microenvironment were analyzed using the Chi square test. Five-year CSS and overall survial was examined using Kaplan--Meier log-rank survival analysis and univariate Cox proportional hazards regression to calculate hazard ratios and 95% confidence intervals. Variables found to be statistically significant (*p* \< 0.05) on univariate analysis were entered into a Cox regression multivariate model using a backward conditional method. A *p* value \< 0.05 was significant. Analyses were performed using SPSS software version 24 (IBM SPSS, Armonk, NY, USA).

Results {#Sec8}
=======

The cohort consisted of 952 patients. Clinical and pathological features are shown in Table [1](#Tab1){ref-type="table"}. Two-thirds of patients included were over the age of 65 years, and 52% were male. Overall, 131 (14%) patients had TNM stage I disease, 445 (47%) had stage II disease, 355 (37%) had stage III disease, and 21 (2%) had stage IV disease; 713 (75%) patients had colon tumors and 239 (25%) had rectal cancer. Venous invasion was present in 321 (34%) tumors, and tumor necrosis was present in 362 (38%) tumors. High-grade tumor budding was present in 28% of tumors, a low-grade inflammatory cell infiltrate was present in 69% of tumors, and 25% of tumors had a high TSP. MMR deficiency was identified in 17% of patients, and 20% of patients had BRAF V600E mutations. The median follow-up for patients was 11.7 years (range 6.4--16.3), with 226 cancer deaths and 271 non-cancer deaths. On univariate survival analysis, T stage (*p* \< 0.001), N stage (*p* \< 0.001), TNM stage (*p* \< 0.001), Ki-67 proliferation index (*p* \< 0.001), MMR (*p* ≤ 0.001), venous invasion (*p* \< 0.001), Klintrup--Makinen (KM) grade (*p* \< 0.001), TSP (*p* \< 0.001), and tumor budding (*p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}) were significantly associated with CSS.Table 1Clinicopathological features of patients with primary operable colorectal cancer and cancer-specific survival*N* (%)\
\[952 patients\]Univariate analysis\
\[CSS\]*p* value*Host characteristics*Age (years)1.00 (0.76--1.32)0.984 \< 65297 (31) \> 65655 (69)Sex1.20 (0.92--1.56)0.176 Female456 (48) Male496 (52)Adjuvant therapy1.03 (0.68--1.28)0.859 Yes105 (34) No204 (64)*Tumor characteristics*Tumor site1.18 (0.89--1.58)0.247 Colon713 (75) Rectum239 (25)Tstage1.97 (1.61--2.41)\< 0.001 140 (4) 2117 (12) 3514 (54) 4281 (30)N stage2.09 (1.78--2.47)\< 0.001 0582 (61) 1253 (27) 2113 (12)TNM stage2.95 (2.38--3.66)\< 0.001 1131 (14) 2445 (47) 3355 (37) 421 (2)Ki-67 proliferation index0.60 (0.46--0.79)\< 0.001 Low450 (48) High491 (52)Mismatch repair status0.64 (0.50--0.82)0.001 Competent763 (83) Deficient162 (17)BRAF status0.91 (0.65--1.28)0.589 Low735 (80) High187 (20)Tumor necrosis1.08 (0.82--1.41)0.579 Low581 (62) High362 (38)Venous invasion2.62 (2.02--3.41)\< 0.001 Absent631 (66) Present321 (34)Klintrup--Makinen grade0.33 (0.23--0.46)\<0.001 Weak651 (69) Strong296 (31)Tumor stroma percentage2.07 (1.58--2.74)\< 0.001 Low704 (75) High232 (25)Tumor budding10.41 (7.76--13.96)\< 0.001 Low684 (72) High268 (28)*CSS* cancer-specific survivalFig. 2Relationship between low- and high-grade tumor budding and cancer-specific survival in patients with primary operable colorectal cancer (*p* \< 0.001). *TB* tumor budding

The relationship between tumor budding, clinicopathological features of primary operable CRC, and tumor budding are shown in Table [2](#Tab2){ref-type="table"}. High-grade budding was associated with T stage (*p* \< 0.001), N stage (*p* \< 0.001), TNM stage (*p* \< 0.001), MMR status (*p* \< 0.05), venous invasion (*p* \< 0.001), KM grade (*p* \< 0.001), and TSP (*p* \< 0.001).Table 2The relationship between tumor budding and clinicopathological features of patients with primary operable colorectal cancerTumor budding \[*N* (%)\]*p* valueLow \[684 (72%)\]High \[268 (28%)\]*Host characteristics*Age (years)0.110 \< 65205 (30)92 (34) \> 65479 (70)176 (66)Sex0.199 Male334 (49)122 (46) Female350 (51)146 (54)*Tumor characteristics*Tumor site0.451 Colon511 (75)202 (75) Rectum173 (25)66 (25)T stage\< 0.001 I38 (6)2 (1) II101 (15)16 (6) III393 (57)121 (45) IV152 (22)129 (48)N stage\< 0.001 0471 (69)111 (42) 1154 (23)99 (37) 255 (8)57 (21)TNM stage\< 0.001 1120 (17)11 (4) 2349 (51)96 (36) 3209 (31)146 (55) 46 (1)15 (5)Proliferation index0.285 Low318 (47)131 (49) High357 (53)134 (51)Mismatch repair status0.012 Competent539 (81)224 (87) Deficient129 (19)33 (13)BRAF status0.066 Low519 (78)216 (83) High143 (22)44 (17)Necrosis0.499 \< 25%417 (62)164 (61) \> 25%259 (38)103 (39)Venous invasion\< 0.001 Absent493 (72)138 (52) Present191 (28)130 (48)Klintrup--Makinen\< 0.001 Weak432 (64)219 (82) strong248 (36)48 (18)Tumor stroma percentage\< 0.001 ≤ 50542 (81)162 (61) \> 50127 (19)105 (39)

The relationship between T stage (1--4), clinicopathological characteristics, and CSS in patients with primary operable CRC are shown in Table [3](#Tab3){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}a--d. T1 and T2 stages were associated with tumor budding (*p* \< 0.01 and *p* \< 0.001, respectively), and T3 stage was associated with venous invasion (*p* \< 0.01), Ki-69 proliferation index (*p* \< 0.01), KM grade (*p* \< 0.05), and tumor budding (*p* \< 0.001). T4 stage was associated with N stage (*p* \< 0.05), venous invasion (*p* \< 0.05), MMR status (*p* \< 0.05), and tumor budding (*p* \< 0.001).Table 3Relationship between T stage, clinicopathological characteristics, and cancer-specific survival in patients with primary operable colorectal cancer T stageUnivariate analysis*p* valueMultivariate analysis*p* value*T1 \[n = 40\]*N stage (0/1/2)1.55 (0.16--14.92)0.704Ki67 proliferation Index (low/high)1.66 (0.17--15.98)0.660Mismatch repair status (competent/deficient)1.44 (0.14--13.85)0.753BRAF status (low/high)0.04 (0--308.53)0.569Tumor necrosis (low/high)0.31 (0.00--375.83)0.468Venous invasion (no/yes)0.46 (0.0--17,931)0.760Klintrup--Makinen grade (weak/strong)0.142 (0.015--1.37)0.0910.97 (0.008--1.19)0.068Tumor stroma percentage (low/high)0.043 (0.00--17,062)0.685Tumor budding (low/high)8.99 (0.92--88.13)0.0598.44 (1.12--303.95)0.042*T2 \[n = 117\]*N stage (0/1/2)1.92 (0.88--4.20)0.104Ki67 proliferation index (low/high)0.557 (0.26--2.02)0.547Mismatch repair status (competent/deficient)0.75 (0.17--3.33)0.704BRAF status (low/high)1.21 (0.34--4.33)0.78Tumor necrosis (low/high)1.41 (0.48--4.13)0.530Venous invasion (no/yes)3.18 (1.12--9.02)0.0302.78 (0.96--8.11)0.060Klintrup--Makinen grade (weak/strong)0.60 (0.22--1.66)0.328Tumor stroma percentage (low/high)1.41 (0.48--4.13)0.530Tumor budding (low/high)8.39 (3.03.03--23.20)\< 0.0017.86 (2.81--21.95)\< 0.001*T3 \[n = 514\]*N stage (0/1/2)1.74 (1.36--2.22)\< 0.0011.20 (0.92--1.56)0.176Ki67 proliferation index (low/high)0.98 (0.97--0.99)0.0020.57 (0.38--0.87)0.008Mismatch repair status (competent/deficient)0.87 (0.50--1.50)0.610BRAF status (low/high)0.96 (0.60--1.56)0.882Tumor necrosis (low/high)1.04 (0.70--1.54)0.848Venous invasion (no/yes)1.78 (1.21--2.62)0.0031.74 (1.16--2.60)0.007Klintrup--Makinen grade (weak/strong)0.37 (0.21--0.65)0.0010.55 (0.30--0.99)0.049Tumor stroma percentage (low/high)1.75 (1.15--2.66)0.0080.96 (0.61--1.53)0.877Tumor budding (low/high)8.98 (4.03--9.39)\< 0.0019.11 (5.92--14.03)\< 0.001*T4 \[n = 281\]*N stage (0/1/2)2.07 (1.62--2.65)\< 0.0011.34 (1.02--1.76)0.032Ki67 proliferation index (low/high)0.78 (0.57--1.18)0.246Mismatch repair status (competent/deficient)0.21 (0.84--0.510.0010.32 (0.13--0.80)0.015BRAF status (low/high)0.84 (0.49--1.41)0.504Tumor necrosis (low/high)0.93 (0.63--1.39)0.736Venous invasion (no/yes)2.99 (1.98--4.52)\< 0.0011.89 (1.22--2.95)0.005Klintrup--Makinen grade (weak/strong)0.35 (0.19--0.63)\<0.0010.62 (0.33--1.14)0.124Tumor stroma percentage (low/high)0.99 (0.98--1.01)0.505Tumor budding (low/high)10.36 (5.96--18.01)\< 0.0018.23 (4.59--14.73)\< 0.001Fig. 3Relationship between tumor budding and cancer-specific survival in **a** T stage 1, **b** T stage 2, **c** T stage 3, and **d** T stage 4 primary operable colorectal cancer (*p* \< 0.05). *Cum* cumulative

The relationship between TNM stage, clinicopathological characteristics, and CSS in patients with primary operable CRC are shown in Table [4](#Tab4){ref-type="table"}. TNM stages I and II were associated with venous invasion (*p* \< 0.05), KM grade (*p* \< 0.05), and tumor budding (*p* \< 0.001). TNM stage III was associated with venous invasion (*p* \< 0.05) and tumor budding (*p* \< 0.001), and TNM stage IV was associated with tumor budding (*p* \< 0.05).Table 4Relationship between TNM stage, clinicopathological characteristics, and cancer-specific survival in patients with primary operable colorectal cancerTNM stageUnivariate analysis*p* valueMultivariate analysis*p* value*Stage 1 \[n = 131\]*Ki67 proliferation index (low/high)0.65 (0.22--1.95)0.445Mismatch repair status (competent/deficient)0.39 (0.0--21.82)0.313BRAF status (low/high)0.57 (0.07--4.38)0.585Tumor necrosis (low/high)1.69 (0.57--5.19)0.353Venous invasion (absent/present)3.44 (1.05--11.22)0.0413.53 (1.02--12.17)0.046Klintrup--Makinen grade (weak/strong)0.28 (0.08--0.89)0.0320.27 (0.08--0.94)0.040Tumor stroma percentage (low/high)1.79 (0.49--6.50)0.378Tumor budding (low/high)9.96 (3.34--29.72)\< 0.0017.90 (2.63--23.74)\< 0.001*Stage 2 \[n = 445\]*Ki67 proliferation index (low/high)0.55 (0.34--0.89)0.014Mismatch repair status (competent/deficient)0.58 (0.29--1.14)0.113BRAF status (low/high)0.97 (0.55--1.73)0.927Tumor necrosis (low/high)0.87 (0.53--1.40)0.555Venous invasion (absent/present)2.34 (1.47--3.74)0.0012.05 (1.27--3.31)0.003Klintrup--Makinen grade (weak/strong)0.41 (0.22--0.77)0.0050.51 (0.26--0.97)0.040Tumor stroma percentage (low/high)3.07 (1.89--4.98)0.0011.53 (0.92--2.54)0.102Tumor budding (low/high)10.21 (6.26--16.64)\< 0.00110.23 (6.12--17.07)\< 0.001*Stage 3 \[n = 355\]*Ki67 proliferation index (low/high)0.66 (0.46--0.95)0.0250.99 (0.99--1.00)0.296Mismatch repair status (competent/deficient)0.83 (0.45--1.50)0.529BRAF status (low/high)0.83 (0.52--1.34)0.453Tumor necrosis (low/high)1.29 (0.90--1.85)0.166Venous invasion (absent/present)1.81 (1.27--2.59)0.0011.55 (1.08--2.23)0.017Klintrup--Makinen grade (weak/strong)0.46 (0.28--0.75)0.05020.62 (0.38--1.01)0.054Tumor stroma percentage (low/high)1.27 (0.87--1.85)0.218Tumor budding (low/high)7.46 (4.87--11.42)\< 0.0019.11 (5.92--14.03)\< 0.001*Stage 4 \[n = 21\]*Ki67 proliferation index (low/high)0.58 (0.21--1.61)0.294Mismatch repair status (competent/deficient)4.27 (0.48--38.24)0.195BRAF status (low/high)0.72 (0.23--2.21)0.561Tumor necrosis (low/high)0.63 (0.18--2.23)0.478venous invasion (absent/present)1.28 (0.47--3.47)0.628Klintrup--Makinen grade (weak/strong)0.31 (0.0--13.67)0.264Tumor stroma percentage (low/high)1.48 (0.55--3.99)0.444Tumor budding (low/high)10.82 (1.38--85.02)0.02410.82 (1.38--85.02)0.024

Tumor budding is an independent prognostic factor in all stages with venous invasion, independent of stages I--III, and KM grade, independent of stages I--II.

Discussion {#Sec9}
==========

The results of the present study show that tumor budding effectively stratifies CSS in patients with primary operable cancer. Furthermore, compared with other tumor characteristics, including T and nodal stage, tumor budding had the highest hazard ratio, approximately three times that of any other tumor characteristic. Therefore, tumor budding is a good candidate to form the basis of a new staging system for primary operable CRC.

It was also of interest that in T1 and T2 tumors, only tumor budding had significant prognostic value. This would indicate that tumor budding occurs early in tumor invasion and may represent aggressive characteristics of malignant tumors, such as loss of cell adhesion and local invasion.[@CR5],[@CR20] Indeed, it may be argued that given its association with other characteristics of the tumor and its microenvironment, tumor budding is the most important component of tumor invasion. Indeed, the prognostic importance of tumor budding in local excision specimens in predicting outcome and/or predictive of nodal metastatic disease in stage pT1 CRCs is increasingly being recognized.[@CR1],[@CR16],[@CR17],[@CR20]

The Ki-67 antigen is widely used to evaluate tumor proliferative activity as autonomous cell proliferation is a main feature of neoplasia. However, despite the clear association of tumor budding with migration and invasion, paradoxically, tumor buds appear not to be associated with proliferation. However, the association between tumor budding intensity and proliferative activity is still poorly understood and it is speculated that host invasion, by budding tumor cells, might be activated only after the cell cycle has been switched off.[@CR2],[@CR15] Further work is required to elucidate the molecular basis of this relationship.

In the present study, it was of interest that other components of the tumor microenvironment had increasing prognostic value in patients with T3 and T4 disease. The basis of this observation is not clear, however it may be that in larger, more invasive tumors, the components of the tumor microenvironment, such as the tumor stroma and inflammatory infiltrate, become more important in determining the future of the primary tumor. For example, the good outcome associated with a pronounced tumor inflammatory cell infiltrate may be due to the effective elimination of the tumor. In contrast, the poor outcome associated with the pronounced tumor stroma may be due to the supportive environment for the tumor. Indeed, Ueno et al. reported an association between fibrotic immature stroma and the intensity of tumor budding as histological dedifferentiation, including dissociation of cancer cells and the first step of invasion. Therefore, the present findings further support a pertinent role of tumor stroma in facilitating tumor cell de-differentiation and dissemination. Further work is required to elucidate the molecular basis of this relationship.

Conclusions {#Sec10}
===========

The findings of the present study indicate that tumor budding effectively stratifies cancer survival in patients with primary operable CRC. This stratification is independent of recognized tumor factors, including TNM stage. Therefore, the ITBCC budding evaluation method should be used to assess tumor budding and may form the basis of a new staging system in patients with CRC.
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